Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Warning Letter
  6. /
  7. Ameriderm Laboratories, Ltd.
WARNING LETTER
•Ameriderm Laboratories, Ltd.•February 13, 2013

Ameriderm Laboratories, Ltd. – FDA Warning Letter, Feb 13, 2013

Record Details

On December 2, 2013, the FDA issued a Warning Letter to Ameriderm Laboratories, Ltd., following an inspection ending February 13, 2013, which identified significant Current Good Manufacturing Practice (CGMP) violations. These violations render the firm's drug products adulterated under 21 U.S.C. 351(a)(2)(B).

Key violations include: 1. **Failure to test water for drug manufacturing:** Water used in OTC drug products was not tested for objectionable microorganisms since 2006, with *Pseudomonas aeruginosa*, *Cronobacter sakazakii*, *Burkholderia pseudomallei*, and *Acinetobacter ursingii* found by investigators. The firm's response to increase sampling was deemed inadequate as it did not meet USP Purified Water standards or include a root cause investigation. This was a repeat observation from June 2011. 2. **Inadequate laboratory facilities:** Contract testing laboratory assay methods for finished products (e.g., Instaclean, PeriShield) were not validated. The firm's response failed to address this. 3. **Failure to establish finished product specifications:** No specifications were established for AmeriWash, DermaFix, Instaclean, and PeriShield, and the firm's response lacked scientific rationale or data to support proposed specifications. This was a repeat observation from June

Company
Ameriderm Laboratories, Ltd.
Inspection date
February 13, 2013
Product type
Drugs
Office
New Jersey District Office
Person
  • Diana Amador-Toro (District Director)
View Company Profile

ID · bff67e67-66dc-4ea8-8492-c58ac4f3f412

Violation Codes10
21 U.S.C. 351(a)(2)(B)21 CFR 21021 CFR 21121 CFR 211.84(d)(2)21 CFR 211.22(b)21 CFR 211.160(b)21 CFR 211.100(a)21 CFR 211.67(b)21 CFR 211.100(b)FD&C Act 501(a)(2)(B)

Full citation text and observation details available on the Dashboard.

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Ameriderm Laboratories, Ltd.
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.